Bafna Pharmaceuticals (NSE:BAFNAPH) Cyclically Adjusted Book per Share: ₹36.16 (As of Mar. 2026)


NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
60 GF Score
Price ₹214.63
GF Value ₹90.68
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals Cyclically Adjusted Book per Share?

Bafna Pharmaceuticals NSE:BAFNAPH +5.00% 60 Cyclically Adjusted Book per Share is ₹36.16 as of Mar. 2026. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹90.68 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Bafna Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was ₹40.645. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹36.16 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Bafna Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-01), Bafna Pharmaceuticals's current stock price is ₹214.63. Bafna Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was ₹36.16. Bafna Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 5.94.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Bafna Pharmaceuticals was 5.31. The lowest was 1.78. And the median was 2.47.


Bafna Pharmaceuticals  (NSE:BAFNAPH) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Bafna Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=214.63/36.16
=5.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Bafna Pharmaceuticals was 5.31. The lowest was 1.78. And the median was 2.47.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Bafna Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Bafna Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals Cyclically Adjusted Book per Share Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 40.79 36.16

Bafna Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.79 0.00 40.12 0.00 36.16

NSE:BAFNAPH vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bafna Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Bafna Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


NSE:BAFNAPH
60GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bafna Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=40.645/164.2724*164.2724
=40.645

Current CPI (Mar. 2026) = 164.2724.

Bafna Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201206 0.000 79.567 0.000
201209 23.350 82.244 46.639
201212 0.000 83.774 0.000
201303 36.156 85.687 69.315
201403 36.909 91.425 66.318
201503 38.475 97.163 65.049
201603 30.956 102.518 49.603
201703 22.869 105.196 35.712
201803 16.033 109.786 23.990
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 8.056 118.202 11.196
201906 0.000 120.880 0.000
201909 6.907 123.175 9.212
201912 0.000 126.235 0.000
202003 21.536 124.705 28.369
202006 0.000 127.000 0.000
202009 22.504 130.118 28.411
202012 0.000 130.889 0.000
202103 23.999 131.771 29.918
202106 0.000 134.084 0.000
202109 27.464 135.847 33.211
202112 0.000 138.161 0.000
202203 26.194 138.822 30.996
202206 0.000 142.347 0.000
202209 27.832 144.661 31.605
202212 0.000 145.763 0.000
202303 31.051 146.865 34.731
202306 0.000 150.280 0.000
202309 34.818 151.492 37.755
202312 0.000 152.924 0.000
202403 34.173 153.035 36.682
202406 0.000 155.789 0.000
202409 34.981 157.882 36.397
202412 0.000 158.323 0.000
202503 35.850 157.552 37.379
202506 0.000 159.755 0.000
202509 38.564 162.289 39.035
202512 0.000 163.281 0.000
202603 40.645 164.272 40.645

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ₹36.16 mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Cyclically Adjusted Book per Share of ₹36.16 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Bafna Pharmaceuticals and its competitors.
Is Bafna Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Bafna Pharmaceuticals' current Cyclically Adjusted Book per Share is ₹36.16. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Bafna Pharmaceuticals' Cyclically Adjusted Book per Share of ₹36.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Bafna Pharmaceuticals and its competitors. Bafna Pharmaceuticals's current Cyclically Adjusted Book per Share is ₹36.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.68, compared to a current price of ₹214.63 — trading 136.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is ₹36.16. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Cyclically Adjusted Book per Share is ₹36.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹214.63 is trading 136.7% above its estimated GF Value™ of ₹90.68. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • Cyclically Adjusted Book per Share: ₹36.16
  • GF Value™: ₹90.68 vs. price of ₹214.63 (136.7% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score

Get the complete analysis for NSE:BAFNAPH

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹214.63
Price
₹90.68
GF Value